ESTRO meets Asia 2024 - Abstract Book

S46

Interdisciplinary – Biomarkers

ESTRO meets Asia 2024

94

Proffered Paper

IL8 with M2 macrophage infiltration as a prognostic marker differentiates WHO Gr.3 and Gr.4 gliomas

Yi-Hsuan Lai 1 , Jang-Chun Lin 1 , Wei-Hsiu Liu 2 , Yu-Jia Chang 3 , Cheng-Chin Lee 4

1 Radiation Oncology, Shuang Ho Hospital, New Taipei City, Taiwan. 2 Neurological Surgery, Tri-Service General Hospital, Taipei, Taiwan. 3 Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan. 4 Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan

Purpose/Objective:

Malignant glioma can be divided into grade 3 (Gr. 3) and grade 4 (Gr. 4). Gr. 3 glioma patients have significantly better overall survival (OS) than those with Gr. 4 glioma, also known as glioblastoma multiforme (GBM). The purpose of our study is to determine prognostic biomarkers that differentiate GBM from malignant gliomas provide information on the association between prognostic genes and immune function.

Material/Methods:

In analyzing two GEO datasets (GSE4290 and GSE109857), differentially expressed genes (DEGs) were identified between Gr. 3 and Gr. 4 gliomas. We use volcano plots and Venn diagrams to find significant DEGs. Forty-eight hub genes with a degree ≥ 2 were extracted from the protein-protein interaction (PPI) network of common DEGs. Further, KEGG pathway enrichment analysis by the DAVID online tool of these 48 hub genes revealed 13 significantly enriched pathways between Gr. 3 and Gr. 4 gliomas. Six candidate prognostic genes for GBM were determined from survival analysis of data from The Cancer Genome Atlas (TCGA), and the results were validated via the Chinese Glioma Genome Atlas (CGGA).

Results:

A total of 21 upregulated and two downregulated hub genes were enriched, and these 23 genes were identified as “Key genes.”